Lorenz Trumper
Overview
Explore the profile of Lorenz Trumper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
8216
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Glaser S, Fischer A, Martinez-Manjon J, Lopez C, Kretzmer H, Burkhardt B, et al.
Leukemia
. 2025 Mar;
PMID: 40065077
No abstract available.
2.
Kurz K, Steinlein S, Kreuz M, Ziepert M, Staiger A, Barth T, et al.
Hemasphere
. 2025 Mar;
9(3):e70093.
PMID: 40060117
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Despite a high cure rate, too many patients show refractory (ref) or relapsed (rel) disease. This study examines the...
3.
Di Stefano G, Fischer A, Chteinberg E, Bens S, Wagener R, Abramov D, et al.
Genes Chromosomes Cancer
. 2025 Jan;
64(1):e70021.
PMID: 39846133
Mature aggressive B-cell lymphomas, such as Burkitt lymphoma (BL) and Diffuse large B-cell lymphoma (DLBCL), show variations in microRNA (miRNA) expression. The entity of High-grade B-cell lymphoma with 11q aberration...
4.
Tournilhac O, Altmann B, Friedrichs B, Bouabdallah K, Leclerc M, Cartron G, et al.
J Clin Oncol
. 2024 Sep;
42(32):3788-3794.
PMID: 39270145
JCO Primary analysis of the phase III randomized AATT study showed that younger patients with peripheral T-cell lymphoma (PTCL) consolidated with autologous or allogeneic transplantation (alloSCT) had similar event-free survival...
5.
Kroger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, et al.
Haematologica
. 2023 Nov;
109(5):1469-1479.
PMID: 37941409
The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma is controversial. Between 2008 and 2014 a total of 217 multiple myeloma...
6.
Treiber H, Ganster C, Schanz J, Shimono J, Zechel S, Pohanyar N, et al.
Ann Hematol
. 2023 Sep;
102(12):3631-3633.
PMID: 37702823
No abstract available.
7.
Treiber H, Nilius-Eliliwi V, Seifert N, Vangala D, Wang M, Seidel S, et al.
Hemasphere
. 2023 Jul;
7(8):e926.
PMID: 37492436
Secondary central nervous system lymphoma (SCNSL) is a rare and difficult to treat type of Non-Hodgkin lymphoma characterized by systemic and central nervous system (CNS) disease manifestations. In this study,...
8.
Braulke F, Zettl F, Ziepert M, Viardot A, Kahl C, Prange-Krex G, et al.
Hemasphere
. 2022 Dec;
6(12):e808.
PMID: 36479544
The incidence of aggressive B-cell lymphomas increases with age, but for elderly or frail patients not eligible for doxorubicin-containing treatment standard therapy remains to be defined. In this prospective, multicenter,...
9.
Bock T, Bewarder M, Cetin O, Fadle N, Regitz E, Schwarz E, et al.
EJHaem
. 2022 Sep;
3(3):739-747.
PMID: 36051037
Burkitt lymphoma (BL) represents the most aggressive B-cell-lymphoma. Beside the hallmark of -translocation, surface B-cell receptor (BCR) is expressed, and mutations in the BCR pathway are frequent. Coincidental infections in...
10.
Shumilov E, Aperdannier L, Schmidt N, Szuszies C, Neesse A, Hoffknecht P, et al.
Cancers (Basel)
. 2022 Aug;
14(15).
PMID: 35954410
COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer...